Investigation of +405 and -460 polymorphisms of vascular endothelial growth factor in psoriasis and short-term responsiveness to efalizumab therapy.
Stefanaki
I
I
Dimisianos
G
G
Antoniou
C
C
Katsambas
A
A
Stratigos
A
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011565:Psoriasis / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; C472181:efalizumab